Anti-vascular endothelial growth factor therapy in clinical practice: Real-world scenarios, limitations, and outcomes. [PDF]
Sharma D, Gupta T.
europepmc +1 more source
Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema. [PDF]
Pak K, Yoon C, Sadda SR.
europepmc +1 more source
Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond. [PDF]
Karpe A, Narula R, Shroff D, Roy A.
europepmc +1 more source
Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]
Sourla E, Zaheer N, Chavan R.
europepmc +1 more source
Comparison of the clinical effect of intravitreal ranibizumab and intravitreal dexamethasone implants in the treatment of retinal vein occlusion complicated with macular oedema: a meta-analysis. [PDF]
Li Y, Hu L, Zu J.
europepmc +1 more source
Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy. [PDF]
Itoh K, Negishi M.
europepmc +1 more source
Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity. [PDF]
Liu Q +8 more
europepmc +1 more source
COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY. [PDF]
Zhu J, Liu J, Chen YX, Yang XW, Zhu RR.
europepmc +1 more source
Efficacy and Safety of Anti-vascular Endothelial Growth Factor (VEGF) Agents in Diabetic Macular Edema. [PDF]
Krishnan B V, Kauser N, Priya G, Sm M.
europepmc +1 more source

